US Court rules in favour of Mylan and Biocon on patent litigation covering Lantus SoloSTAR device

The US Court has ruled in favour of Mylan and Biocon on patent litigation covering Lantus SoloSTAR device. Lantus SoloSTAR is an insulin pen for diabetes biosimilar Insulin Glargine.

This would remove legal hurdles for Mylan and Biocon’s launch of biosimilar Lantus. The launch is expected in June 2020, said a Kotak Institutional report. However, Kotak still expects the launch to be at-risk as Sanofi may escalate the litigation to a higher court.

Kotak has a sell rating on Biocon. According to them, the commercial execution is going to be key because of the steady price decline in Insulin Glargine.